Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-based calcineurin inhibitor-free regimen with thymoglobulin and immunoglobulin versus conventional calcineurin inhibitor regimen in standard-risk kidney transplant recipients
2010-019337-10Phase 4Active
- Sponsor
- Bellvitge University Hospital
- Start
- Mar 2012
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus, tacrolimus, antithymocyte globulin rabbit and immune serum globulin in end-stage kidney disease (ESKD) and kidney transplant (2 arms), sponsored by Bellvitge University Hospital. Primary endpoint: Renal function at month 6. Started Mar 2012; status: active.
02
Drugs
sirolimustacrolimusantithymocyte globulin rabbitimmune serum globulin
03
Conditions
end-stage kidney disease (ESKD)kidney transplant
Beyond the preview
Go deeper on 2010-019337-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019337-10.